Continued thienopyridine beyond one year, in conjunction with aspirin, showed significant reductions in stent thrombosis and myocardial infarction (MI) in patients with everolimus-eluting stents (EES), according to the results of a study presented Oct. 11 at TCT 2015 and simultaneously published in JACC: Cardiovascular Interventions.

James B. Hermiller, MD, FACC, et al., sought to assess the outcomes of EES patients from the DAPT Trial who continued thienopyridine treatment versus those taking aspirin alone 12 – 30 months after stent placement.

The results of the study showed that EES patients who continued thienopyridine treatment, in addition to taking aspirin, had significantly less incidences of stent thrombosis and MI. However, continued treatment did not reduce a composite of death, MI and stroke, and was associated with higher rates of moderate or severe bleeding.

The authors of the study note that the results “suggest that the therapeutic window for benefit (vs. risk) of continued thienopyridine therapy [in EES patients] may be narrow.” 

Keywords: Transcatheter Cardiovascular Therapeutics, Drug-Eluting Stents, Risk, Risk Assessment, Sirolimus, Stents

< Back to Listings